Vadim V. Baykov
Research Subjects
Research Interests
Vadim V. Baykov has a total of 283 co-authors. Here are the top co-authors by number of shared publications:
- Aleksander Dmitrievich Kulagin
Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
11 shared publications - Lyudmila Stepanovna Zubarovskaya
I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Health of the Russian Federation
8 shared publications - Vsevolod Gennadevich Potapenko
City Clinical Hospital No. 31, 3 Dinamo pr-t, Saint Petersburg, Russian Federation, 197110
8 shared publications - Andrei Vadimovich Kozlov
Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of St. Petersburg, Ministry of Health of Russia
7 shared publications - Ilya Viktorovich Kazantsev
Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of St. Petersburg, Ministry of Health of Russia
7 shared publications - P. S. Tolkunova
Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of St. Petersburg, Ministry of Health of Russia
7 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (3) , 150-158
The role of second-look biopsy in children with lymphoma
Objective. Second look biopsy is the standard for confirming relapsed and refractory (R-R) lymphoma in children. However, in real-world clinical practice, R-R lymphomas sometimes may be diagnosed without second-look biopsy, relying solely on imaging data. This study is the first to comparatively analyze both approaches in children. Materials and methods. A total of 198 pediatric patients with lymphoma were included in the study. Of these, 181 children were diagnosed with R-R lymphoma after second-look biopsy (n = 111) or based solely on imaging (no second-look biopsy) (n = 70), in 17 patients with suspected R-R lymphoma, relapse was excluded after second-look biopsy. We assessed the sensitivity and negative predictive value of second-look biopsy. And compared the incidence of subsequent relapse and survival in patients with R-R lymphoma according to availability of second-look biopsy. Results. The sensitivity of second-look biopsy for confirming R-R lymphoma was 96.5%, and the negative predictive value was 76.5%. The cumulative incidence of relapse was 78.6% in children with R-R B-cell non-Hodgkin lymphoma that was previously confirmed by second-look biopsy, compared with 28.7% in patients with R-R B-cell non-Hodgkin lymphoma confirmed only by imaging (without second-look biopsy) (p = 0.003). Conclusions. Thus, these results indicate the need for second-look biopsy to confirm the diagnosis of R-R lymphoma in children, as otherwise there is a risk of overdiagnosis. However, given the suboptimal negative predictive value of second-look biopsy (76.5%), a diagnosis of relapse or primary refractoriness of lymphoma may be made in some patients based on clinical presentation and imaging data.
- 19 August 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (3) , 150-158
Open AccessThe role of second-look biopsy in children with lymphoma
Objective. Second look biopsy is the standard for confirming relapsed and refractory (R-R) lymphoma in children. However, in real-world clinical practice, R-R lymphomas sometimes may be diagnosed without second-look biopsy, relying solely on imaging data. This study is the first to comparatively analyze both approaches in children. Materials and methods. A total of 198 pediatric patients with lymphoma were included in the study. Of these, 181 children were diagnosed with R-R lymphoma after second-look biopsy (n = 111) or based solely on imaging (no second-look biopsy) (n = 70), in 17 patients with suspected R-R lymphoma, relapse was excluded after second-look biopsy. We assessed the sensitivity and negative predictive value of second-look biopsy. And compared the incidence of subsequent relapse and survival in patients with R-R lymphoma according to availability of second-look biopsy. Results. The sensitivity of second-look biopsy for confirming R-R lymphoma was 96.5%, and the negative predictive value was 76.5%. The cumulative incidence of relapse was 78.6% in children with R-R B-cell non-Hodgkin lymphoma that was previously confirmed by second-look biopsy, compared with 28.7% in patients with R-R B-cell non-Hodgkin lymphoma confirmed only by imaging (without second-look biopsy) (p = 0.003). Conclusions. Thus, these results indicate the need for second-look biopsy to confirm the diagnosis of R-R lymphoma in children, as otherwise there is a risk of overdiagnosis. However, given the suboptimal negative predictive value of second-look biopsy (76.5%), a diagnosis of relapse or primary refractoriness of lymphoma may be made in some patients based on clinical presentation and imaging data.
- Open Access
- 1 July 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (3)
Efficacy and Safety of Various Treatment Regimens for Primary CNS Lymphoma: Results of a Retrospective Study Based on the Data from Nine Saint Petersburg Medical Institutions
BACKGROUND. In the Russian Federation, systematic evidence of treatment outcomes and prognosis evaluation in primary CNS lymphoma (PCNSL) patients is currently unavailable. AIM. To study the clinical and epidemiological characteristics as well as current medical practice and the first-line therapy outcomes in PCNSL patients. MATERIALS & METHODS. The study enrolled 127 adults with histologically verified PCNSL diagnosis treated from 2010 to 2024 at nine medical institutions in Saint Petersburg. Absolute majority (n = 119; 94 %) of them received various regimens of chemo- and/or immunochemotherapy (ICT). High-dose methotrexate (HD-МТХ) protocols were administered in 103 (87 %) cases, 86 % (n = 101) of PCNSL patients received rituximab. RESULTS. Response assessment was analyzed in 111 (87 %) patients. Objective response (OR) to the first-line therapy was 72 % (n = 80) including complete remissions in 38 (34 %) patients. With the follow-up of 12 months (range 0.4–151.1 months), the 2-year overall survival (OS) was 43 % (95 % confidence interval [95% CI] 34–54 %), and the 2-year event-free survival (EFS) was 30 % (95% CI 22–40 %). Prognostic factors included ECOG status and HD-МТХ administration. After ICT, 28 (38 %) patients with OR received radiation or high-dose therapy with autologous hematopoietic stem cell transplantation as consolidation treatment. Consolidation stage, irrespective of the chosen option, was associated with better rates of long-term survival: the 2-year OS was 78 % (95% CI 62–100 %), the 2-year EFS was 59 % (95% CI 41–84 %). CONCLUSION. The clinical profile of PCNSL patients, as revealed in this study, is generally consistent with published literature. Most patients received the treatment regimens in accordance with the international guidelines, however, in a part of them, suboptimal treatment was used. The best rates of long-term survival were reported in patients who achieved OR and subsequently received consolidation therapy.
- 1 July 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (3)
Open AccessEfficacy and Safety of Various Treatment Regimens for Primary CNS Lymphoma: Results of a Retrospective Study Based on the Data from Nine Saint Petersburg Medical Institutions
BACKGROUND. In the Russian Federation, systematic evidence of treatment outcomes and prognosis evaluation in primary CNS lymphoma (PCNSL) patients is currently unavailable. AIM. To study the clinical and epidemiological characteristics as well as current medical practice and the first-line therapy outcomes in PCNSL patients. MATERIALS & METHODS. The study enrolled 127 adults with histologically verified PCNSL diagnosis treated from 2010 to 2024 at nine medical institutions in Saint Petersburg. Absolute majority (n = 119; 94 %) of them received various regimens of chemo- and/or immunochemotherapy (ICT). High-dose methotrexate (HD-МТХ) protocols were administered in 103 (87 %) cases, 86 % (n = 101) of PCNSL patients received rituximab. RESULTS. Response assessment was analyzed in 111 (87 %) patients. Objective response (OR) to the first-line therapy was 72 % (n = 80) including complete remissions in 38 (34 %) patients. With the follow-up of 12 months (range 0.4–151.1 months), the 2-year overall survival (OS) was 43 % (95 % confidence interval [95% CI] 34–54 %), and the 2-year event-free survival (EFS) was 30 % (95% CI 22–40 %). Prognostic factors included ECOG status and HD-МТХ administration. After ICT, 28 (38 %) patients with OR received radiation or high-dose therapy with autologous hematopoietic stem cell transplantation as consolidation treatment. Consolidation stage, irrespective of the chosen option, was associated with better rates of long-term survival: the 2-year OS was 78 % (95% CI 62–100 %), the 2-year EFS was 59 % (95% CI 41–84 %). CONCLUSION. The clinical profile of PCNSL patients, as revealed in this study, is generally consistent with published literature. Most patients received the treatment regimens in accordance with the international guidelines, however, in a part of them, suboptimal treatment was used. The best rates of long-term survival were reported in patients who achieved OR and subsequently received consolidation therapy.
- 24 December 2025
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Grekov's Bulletin of Surgery
- Vol. 184 (5)
Intraoperative fluorescence imaging of lung neoplasms in near-infrared light
INTRODUCTION. In surgical treatment of early peripheral lung cancer, accurate intraoperative visualization of the tumor and determination of tumor growth boundaries remain a problem.The OBJECTIVE was to develop a methodology and analyze the first results of intraoperative infrared fluorescence diagnosis of lung neoplasms.METHODS AND MATERIALS. The study included 27 operated patients with lung neoplasms of various histological types. Each patient immediately after performing access, as well as on the ex vivo, underwent an attempt at fluorescence imaging of the removed tumors in the near-infrared spectrum, as well as the presence of other foci of fluorescence. The fluorescence intensity was quantified. Indocyanine green lyophilizate with Human Albumin 20 % was used as a fluorescent agent, and the MMC SCOPE ICG system was used to visualize infrared fluorescence.RESULTS. Infrared fluorescence was used to visualize 21 out of 31 (68 %) neoplasms in 20 out of 27 (74 %) patients. When comparing fluorescent and non-fluorescent foci, there was no correlation between the presence of fluorescence and the histological structure, the size of the neoplasms and the presence of invasion of the visceral pleura. Fluorescence diagnostics also revealed in 3 patients (11 %) an additional 4 CT-negative foci ranging in size from 0.5 to 10 mm, all of which turned out to be malignant tumors.CONCLUSION. The method of fluorescent intraoperative diagnosis is safe and informative, it allows to visualize intrapulmonary neoplasms in 74 % of patients, as well as to identify Rg-negative tumor foci in 11 % of patients.
- 24 December 2025
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in Grekov's Bulletin of Surgery
- Vol. 184 (5)
Intraoperative fluorescence imaging of lung neoplasms in near-infrared light
INTRODUCTION. In surgical treatment of early peripheral lung cancer, accurate intraoperative visualization of the tumor and determination of tumor growth boundaries remain a problem.The OBJECTIVE was to develop a methodology and analyze the first results of intraoperative infrared fluorescence diagnosis of lung neoplasms.METHODS AND MATERIALS. The study included 27 operated patients with lung neoplasms of various histological types. Each patient immediately after performing access, as well as on the ex vivo, underwent an attempt at fluorescence imaging of the removed tumors in the near-infrared spectrum, as well as the presence of other foci of fluorescence. The fluorescence intensity was quantified. Indocyanine green lyophilizate with Human Albumin 20 % was used as a fluorescent agent, and the MMC SCOPE ICG system was used to visualize infrared fluorescence.RESULTS. Infrared fluorescence was used to visualize 21 out of 31 (68 %) neoplasms in 20 out of 27 (74 %) patients. When comparing fluorescent and non-fluorescent foci, there was no correlation between the presence of fluorescence and the histological structure, the size of the neoplasms and the presence of invasion of the visceral pleura. Fluorescence diagnostics also revealed in 3 patients (11 %) an additional 4 CT-negative foci ranging in size from 0.5 to 10 mm, all of which turned out to be malignant tumors.CONCLUSION. The method of fluorescent intraoperative diagnosis is safe and informative, it allows to visualize intrapulmonary neoplasms in 74 % of patients, as well as to identify Rg-negative tumor foci in 11 % of patients.
- Open Access
- 1 October 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (4) , 355-371
Возможности терапии хронической активной болезни и вторичного гемофагоцитарного синдрома, ассоциированных с вирусом Эпштейна—Барр (серия клинических наблюдений)
Epstein-Barr virus (EBV) infection is characterized by a benign course except for the rare variants which include chronic active disease (EBV-CAD) and secondary hemophagocytic syndrome (EBV-sHPS). sHPS is a life-threatening disorder associated with severely impaired immune response regulation. The pathogenesis is based on the activation of cytotoxic Т-lymphocytes, NK-cells and macrophages with overproduction of proinflammatory cytokines and ineffective systemic inflammatory response. The most common manifestations are persistent febrile fever, moderate cytopenia, cytolytic and cholestatic syndromes, and multiple organ failure. One of the most effective agents for the control of hyperergic reaction is etoposide. The present paper reports the outcomes of treating 5 EBV-sHPS patients and 1 EBV-CAD patient. All of them showed fever, liver dysfunction, hypofibrinogenemia, and cytopenia. In sHPS patients, pronounced hyperferritinemia was identified. At the time of submitting the present paper, 3 patients with no evident disease were still followed up.
- 1 October 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (4) , 355-371
Open AccessВозможности терапии хронической активной болезни и вторичного гемофагоцитарного синдрома, ассоциированных с вирусом Эпштейна—Барр (серия клинических наблюдений)
Epstein-Barr virus (EBV) infection is characterized by a benign course except for the rare variants which include chronic active disease (EBV-CAD) and secondary hemophagocytic syndrome (EBV-sHPS). sHPS is a life-threatening disorder associated with severely impaired immune response regulation. The pathogenesis is based on the activation of cytotoxic Т-lymphocytes, NK-cells and macrophages with overproduction of proinflammatory cytokines and ineffective systemic inflammatory response. The most common manifestations are persistent febrile fever, moderate cytopenia, cytolytic and cholestatic syndromes, and multiple organ failure. One of the most effective agents for the control of hyperergic reaction is etoposide. The present paper reports the outcomes of treating 5 EBV-sHPS patients and 1 EBV-CAD patient. All of them showed fever, liver dysfunction, hypofibrinogenemia, and cytopenia. In sHPS patients, pronounced hyperferritinemia was identified. At the time of submitting the present paper, 3 patients with no evident disease were still followed up.
- Open Access
- 2 September 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (3) , 153-158
Mosunetuzumab for relapsed or refractory follicular lymphoma: a case study
Recent advances in the diagnosis and understanding of follicular lymphoma (FL) pathogenesis have had a significant impact on therapeutic tactics. The life expectancy of patients has increased significantly. Currently, the 5-year overall survival of FL patients achieved 90 %, and its median is approaching 20 years. However, FL remains an incurable disease with periods of remission and relapse, requiring multiple therapy courses throughout the patient’s life.The main problem is the treatment of patients with refractory/relapsed forms, especially after 3rd line of therapy, as well as with a primarily resistant course and early (in the first 2 years) relapses. Therefore, despite the indolent FL course in most patients, there remains a need for new drugs that can ensure increased treatment efficacy with minimal toxicity and simultaneously maintain a high quality of life, mainly in the presence of primary refractoriness, early progression and in later lines of therapy. In recent years, new targeted drugs have been studied – phosphoinositide 3-kinase, enhancer of zeste homolog 2 inhibitors, as well as immunological drugs (CAR-T therapy (CAR – chimeric antigen receptor) and bispecific antibodies).The article presents the possibilities of treatment for refractory/relapsed FL as 3rd and subsequent therapy lines.
- 2 September 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (3) , 153-158
Open AccessMosunetuzumab for relapsed or refractory follicular lymphoma: a case study
Recent advances in the diagnosis and understanding of follicular lymphoma (FL) pathogenesis have had a significant impact on therapeutic tactics. The life expectancy of patients has increased significantly. Currently, the 5-year overall survival of FL patients achieved 90 %, and its median is approaching 20 years. However, FL remains an incurable disease with periods of remission and relapse, requiring multiple therapy courses throughout the patient’s life.The main problem is the treatment of patients with refractory/relapsed forms, especially after 3rd line of therapy, as well as with a primarily resistant course and early (in the first 2 years) relapses. Therefore, despite the indolent FL course in most patients, there remains a need for new drugs that can ensure increased treatment efficacy with minimal toxicity and simultaneously maintain a high quality of life, mainly in the presence of primary refractoriness, early progression and in later lines of therapy. In recent years, new targeted drugs have been studied – phosphoinositide 3-kinase, enhancer of zeste homolog 2 inhibitors, as well as immunological drugs (CAR-T therapy (CAR – chimeric antigen receptor) and bispecific antibodies).The article presents the possibilities of treatment for refractory/relapsed FL as 3rd and subsequent therapy lines.
- Open Access
- 2 September 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (3) , 142-148
Difficulties of primary diagnosis in patients with suspected systemic mastocytosis
Background. Mastocytosis is a rare myeloproliferative disease based on clonal hematopoiesis of mast cells, with accumulation of mast cells in various tissues and organs. The cutaneous mastocytosis is common in the pediatric population and, in general, progression to aggressive forms is not typical. In the adult population, there is systemic mastocytosis with a predominance of indolent and smoldering forms according to the literature, but there aren’t epidemiological data for the Russian Federation.Aim. To evaluate the results of primary diagnostics obtained during the examination of 70 patients with suspected systemic mastocytosis.Materials and methods. The histological studies of the skin and bone marrow, mutations in the c-kit gene in the bone marrow and serum tryptase level were examined in the Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation in accordance with WHO 2017 criteria.Results. The diagnostic results of 70 patients with suspected mastocytosis, the diagnosis was confirmed in 71.4 % (n = 50) of patients, of which systemic mastocytosis accounted for 82 % (n = 41). The 2 most common categories were identified: indolent systemic mastocytosis in 23 (56 %) patients and widespread forms in 15 (36.5 %), with a median time of diagnosis of 12 and 5 years, respectively.Conclusion. The late diagnosis is noted in all subgroups of systemic mastocytosis.
- 2 September 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (3) , 142-148
Open AccessDifficulties of primary diagnosis in patients with suspected systemic mastocytosis
Background. Mastocytosis is a rare myeloproliferative disease based on clonal hematopoiesis of mast cells, with accumulation of mast cells in various tissues and organs. The cutaneous mastocytosis is common in the pediatric population and, in general, progression to aggressive forms is not typical. In the adult population, there is systemic mastocytosis with a predominance of indolent and smoldering forms according to the literature, but there aren’t epidemiological data for the Russian Federation.Aim. To evaluate the results of primary diagnostics obtained during the examination of 70 patients with suspected systemic mastocytosis.Materials and methods. The histological studies of the skin and bone marrow, mutations in the c-kit gene in the bone marrow and serum tryptase level were examined in the Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation in accordance with WHO 2017 criteria.Results. The diagnostic results of 70 patients with suspected mastocytosis, the diagnosis was confirmed in 71.4 % (n = 50) of patients, of which systemic mastocytosis accounted for 82 % (n = 41). The 2 most common categories were identified: indolent systemic mastocytosis in 23 (56 %) patients and widespread forms in 15 (36.5 %), with a median time of diagnosis of 12 and 5 years, respectively.Conclusion. The late diagnosis is noted in all subgroups of systemic mastocytosis.
- Open Access
- 1 July 2024
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 17 (3) , 213-224
Clinical Profile of Adults with Inherited Bone Marrow Failure Syndromes: Results of an Ambispective Clinical Single-Center Study
BACKGROUND. Inherited bone marrow failure syndromes (IBMFS) is a heterogenous group of rare genetically determined diseases with variable hematologic and nonhematologic manifestations. The implementation of highly specific methods of genetic diagnosis advanced the understanding of IBMFS and allowed its application also beyond pediatrics. That presupposes an awareness of clinical features and reference points for recognizing IBMFS in adults. AIM. To describe the clinical profile of adult IBMFS patients. MATERIALS & METHODS. This ambispective single-center study enrolled 35 patients (10 women and 25 men) with IBMFS. Patients were aged 18–51 years (median 26 years). The following IBMFS were identified: congenital dyskeratosis (n = 10; 28 %), Diamond-Blackfan anemia (n = 9; 26 %), Fanconi anemia (n = 7; 20 %), GATA2 deficiency (n = 3; 8 %), Shwachman-Diamond syndrome (n = 1; 3 %), GATA2 deficiency (n = 1; 3 %), amegakaryocytic thrombocytopenia (n = 1; 3 %), bone marrow failure syndrome type 3 (n = 1; 3 %), severe congenital neutropenia (n = 1; 3 %), bone marrow failure with SAMD9 mutation (n = 1; 3 %). These diseases were analyzed in terms of hematologic and nonhematologic manifestations as well as main diagnosis stages and factors that contribute to recognizing IBMFS. RESULTS. Monolinear cytopenia, bilinear cytopenia, and pancytopenia were identified at hematologic onset in 18 (52 %), 6 (17 %), and 11 (31 %) patients, respectively. The median age of patients by hematologic onset was 15 years (range 0–43 years), in 14 (40 %) patients cytopenia was newly diagnosed at the age of > 18 years. In 23 (63 %) patients hypocellular bone marrow was reported, 7 (20 %) and 5 (14 %) patients had pure red cell aplasia and multilineage myelodysplasia, respectively. Chromosomal aberrations were identified in 2 patients. Paroxysmal nocturnal hemoglobinuria clone was detected in none of 27 examined patients. In 12 (34 %) patients, the criteria for non-severe aplastic anemia were met. Temporary partial or complete spontaneous hematologic recovery was observed in 6 (17 %) patients. Abnormalities with partial or complete organ dysfunctions were identified in 14 patients, whereas all patients showed minor congenital defects. All 7 Fanconi anemia patients and 9 out of 10 congenital dyskeratosis patients demonstrated organ damage specific to these diseases. Family history predominantly showing malignant neoplasms in relatives was reported in 15 (43 %) patients. Initial hematological examination yielded suspect of IBMFS in 12 (34 %) patients with the median time to diagnosis of 6 months. In 23 (66 %) patients, hematologic defects with cytopenia were erroneously accounted for by various acquired diseases, which led to a delayed correct diagnosis (median 7 years). The key factors in suspecting IBMFS were organ abnormalities and positive family history. The IBMFS diagnosis was verified by the next-generation sequencing (NGS) in 29 (83 %) patients and by other specific methods in 4 (11 %) patients. In 2 patients, the diagnosis was established on the basis of complete clinical criteria alone. CONCLUSION. IBMFS is a matter of current concern and a difficult-to-recognize clinical challenge in adult hematology patients. Differential diagnosis of acquired and congenital bone marrow failure needs to be performed irrespective of patient’s age. A detailed physical examination of patients, family history, and critical analysis of clinical profile and disease course allow for early suspicion of IBMFS. Suspected IBMFS is an indication for referral of patients to specialized centers and performing genetic diagnostics including NGS.
- 1 July 2024
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 17 (3) , 213-224
Open AccessClinical Profile of Adults with Inherited Bone Marrow Failure Syndromes: Results of an Ambispective Clinical Single-Center Study
BACKGROUND. Inherited bone marrow failure syndromes (IBMFS) is a heterogenous group of rare genetically determined diseases with variable hematologic and nonhematologic manifestations. The implementation of highly specific methods of genetic diagnosis advanced the understanding of IBMFS and allowed its application also beyond pediatrics. That presupposes an awareness of clinical features and reference points for recognizing IBMFS in adults. AIM. To describe the clinical profile of adult IBMFS patients. MATERIALS & METHODS. This ambispective single-center study enrolled 35 patients (10 women and 25 men) with IBMFS. Patients were aged 18–51 years (median 26 years). The following IBMFS were identified: congenital dyskeratosis (n = 10; 28 %), Diamond-Blackfan anemia (n = 9; 26 %), Fanconi anemia (n = 7; 20 %), GATA2 deficiency (n = 3; 8 %), Shwachman-Diamond syndrome (n = 1; 3 %), GATA2 deficiency (n = 1; 3 %), amegakaryocytic thrombocytopenia (n = 1; 3 %), bone marrow failure syndrome type 3 (n = 1; 3 %), severe congenital neutropenia (n = 1; 3 %), bone marrow failure with SAMD9 mutation (n = 1; 3 %). These diseases were analyzed in terms of hematologic and nonhematologic manifestations as well as main diagnosis stages and factors that contribute to recognizing IBMFS. RESULTS. Monolinear cytopenia, bilinear cytopenia, and pancytopenia were identified at hematologic onset in 18 (52 %), 6 (17 %), and 11 (31 %) patients, respectively. The median age of patients by hematologic onset was 15 years (range 0–43 years), in 14 (40 %) patients cytopenia was newly diagnosed at the age of > 18 years. In 23 (63 %) patients hypocellular bone marrow was reported, 7 (20 %) and 5 (14 %) patients had pure red cell aplasia and multilineage myelodysplasia, respectively. Chromosomal aberrations were identified in 2 patients. Paroxysmal nocturnal hemoglobinuria clone was detected in none of 27 examined patients. In 12 (34 %) patients, the criteria for non-severe aplastic anemia were met. Temporary partial or complete spontaneous hematologic recovery was observed in 6 (17 %) patients. Abnormalities with partial or complete organ dysfunctions were identified in 14 patients, whereas all patients showed minor congenital defects. All 7 Fanconi anemia patients and 9 out of 10 congenital dyskeratosis patients demonstrated organ damage specific to these diseases. Family history predominantly showing malignant neoplasms in relatives was reported in 15 (43 %) patients. Initial hematological examination yielded suspect of IBMFS in 12 (34 %) patients with the median time to diagnosis of 6 months. In 23 (66 %) patients, hematologic defects with cytopenia were erroneously accounted for by various acquired diseases, which led to a delayed correct diagnosis (median 7 years). The key factors in suspecting IBMFS were organ abnormalities and positive family history. The IBMFS diagnosis was verified by the next-generation sequencing (NGS) in 29 (83 %) patients and by other specific methods in 4 (11 %) patients. In 2 patients, the diagnosis was established on the basis of complete clinical criteria alone. CONCLUSION. IBMFS is a matter of current concern and a difficult-to-recognize clinical challenge in adult hematology patients. Differential diagnosis of acquired and congenital bone marrow failure needs to be performed irrespective of patient’s age. A detailed physical examination of patients, family history, and critical analysis of clinical profile and disease course allow for early suspicion of IBMFS. Suspected IBMFS is an indication for referral of patients to specialized centers and performing genetic diagnostics including NGS.
- Open Access
- 1 July 2024
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 17 (3) , 291-334
National Clinical Guidelines on Diagnosis and Treatment of Ph-Negative Myeloproliferative Neoplasms (Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis) (Edition 2024)
The development of National clinical guidelines on diagnosis and treatment of Ph-negative myeloproliferative neoplasms provides the knowledge basis for decision making in diagnosis, therapy, prevention, and rehabilitation in compliance with evidence-based medicine principles in order to ensure appropriate medical care in a particular clinical setting. The clinical guidelines underly the choice of optimal methods of diagnosis, therapy, prevention, and rehabilitation as part of a patient’s medical care, the development of criteria for the assessment of medical care quality, medical care standards, medical care procedures, setting standards on equipment and management of diagnostic and therapeutic procedures, and provision of continuous medical education and advanced training for healthcare professionals. In 2013, a working group was formed to develop and formulate clinical guidelines on the treatment of myeloproliferative neoplasms. These guidelines were first published in 2014, afterwards they were revised and republished. The dynamic development of current hematology presupposes constant updating of knowledge and implementation of new diagnosis and treatment methods in clinical practice. In this context, clinical guidelines present a dynamic document to be continuously amended, expanded, and updated in accordance with scientific findings and new requirements of specialists who are directly involved in treatment activities. The present edition is an upgraded version of clinical guidelines with updated information on classification, diagnosis, prognosis, current methods of therapy, and their efficacy and tolerability assessment. The guidelines are intended for oncologists, hematologists, healthcare executives, and medical students.
- 1 July 2024
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 17 (3) , 291-334
Open AccessNational Clinical Guidelines on Diagnosis and Treatment of Ph-Negative Myeloproliferative Neoplasms (Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis) (Edition 2024)
The development of National clinical guidelines on diagnosis and treatment of Ph-negative myeloproliferative neoplasms provides the knowledge basis for decision making in diagnosis, therapy, prevention, and rehabilitation in compliance with evidence-based medicine principles in order to ensure appropriate medical care in a particular clinical setting. The clinical guidelines underly the choice of optimal methods of diagnosis, therapy, prevention, and rehabilitation as part of a patient’s medical care, the development of criteria for the assessment of medical care quality, medical care standards, medical care procedures, setting standards on equipment and management of diagnostic and therapeutic procedures, and provision of continuous medical education and advanced training for healthcare professionals. In 2013, a working group was formed to develop and formulate clinical guidelines on the treatment of myeloproliferative neoplasms. These guidelines were first published in 2014, afterwards they were revised and republished. The dynamic development of current hematology presupposes constant updating of knowledge and implementation of new diagnosis and treatment methods in clinical practice. In this context, clinical guidelines present a dynamic document to be continuously amended, expanded, and updated in accordance with scientific findings and new requirements of specialists who are directly involved in treatment activities. The present edition is an upgraded version of clinical guidelines with updated information on classification, diagnosis, prognosis, current methods of therapy, and their efficacy and tolerability assessment. The guidelines are intended for oncologists, hematologists, healthcare executives, and medical students.
- Open Access
- 3 April 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (2) , 46-55
Cladribine chemotherapy of multifocal, multisystemic form of Rosai–Dorfman disease: literature review and case report
Rosai–Dorfman disease is the most frequent variant of non-Langerhans cell histiocytosis. Local forms can be resected or irradiated. If the process involves multiple organs, systemic chemotherapy can cure some patients. This article includes literature review and a case report of a 34-year-old patient with multifocal, multisystemic form of Rosai–Dorfman disease with bone and pleural involvement. The diagnosis was based on histological, immunohistochemical, and molecular studies of tumor tissue. Since November 2021, 6 courses of chemotherapy with cladribine and 8 infusions of zolendronic acid were carried out with achievement of durable remission. The tolerance was acceptable.
- 3 April 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (2) , 46-55
Open AccessCladribine chemotherapy of multifocal, multisystemic form of Rosai–Dorfman disease: literature review and case report
Rosai–Dorfman disease is the most frequent variant of non-Langerhans cell histiocytosis. Local forms can be resected or irradiated. If the process involves multiple organs, systemic chemotherapy can cure some patients. This article includes literature review and a case report of a 34-year-old patient with multifocal, multisystemic form of Rosai–Dorfman disease with bone and pleural involvement. The diagnosis was based on histological, immunohistochemical, and molecular studies of tumor tissue. Since November 2021, 6 courses of chemotherapy with cladribine and 8 infusions of zolendronic acid were carried out with achievement of durable remission. The tolerance was acceptable.
- Open Access
- 14 February 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (1) , 22-31
The treatment of relapsed/refractory anaplastic large cell lymphoma expressing the anaplastic lymphoma kinase: a single-center experience
Anaplastic large cell lymphoma (ALCL) expressing the anaplastic lymphoma kinase (ALK) (ALK+ ALCL) is a rare type of lymphoma which comprises 10-15% of all non-Hodgkin lymphomas in children and 2–3% in young adults. Relapsed/refractory disease occurs even more rarely (25–40% of all cases). There is as yet no standard treatment for relapsed/refractory ALK+ ALCL. Patients with ALK+ ALCL usually present at advanced stages of the disease with extranodal involvement (skin, soft tissues, bones, lungs, liver, spleen and bone marrow) and B symptoms. ALK-positive ALCL affects males more often than females. There are two morphological variants: the common type (65% of cases) and the non-common type which is associated with a poorer prognosis. ALK+ ALCLs are often associated with t(2;5) and t(1;2), resulting in the formation of the NPM-ALK and the TPM3-ALK fusion proteins, respectively. Data about the treatment of relapsed/refractory ALK+ ALCL are limited. Earlier, targeted therapies (brentuximab vedotin (BV), ALK inhibitors) and risk-adapted chemotherapy followed by hematopoietic stem cell transplantation (HSCT) for remission consolidation were shown to be highly effective. A total of 15 patients with relapsed/refractory ALK+ ALCL were treated at the R.M. Gorbacheva Research Institute starting from 2002. Fourteen (93%) patients had ALK-positive ALCL of common morphology and one (7%) patient had the non-common variant (histiocytic). The study was approved by the Independent Ethics Committee and the Scientific Council of the Pavlov University. The expression of CD3 on tumor cells was assessed (CD3 positive: n = 4 (27%), CD3 negative: n = 8 (53%), no data: n = 3 (20%). The median age at the diagnosis was 26 years (11 months– 37 years). The median follow-up from the diagnosis was 9 years (1–19 years). Nine (60%) patients were aged 18 years and six (40%) patients were aged 18 years. There were 10 (67%) males and 5 (33%) females. At onset, 2 (13%) patients were diagnosed with early-stage disease (stage II), while the others were diagnosed with advanced-stage disease: 2 (13%) patients had stage III disease and 11 (74%) had stage IV disease. Staging was performed according to the St. Jude staging system (in children) and the Ann Arbour staging classification (in adults). Thirteen (86%) patients had extranodal involvement. Four (27%) patients had refractory disease (progression within the first three months or the absence of complete remission after the first-line treatment) and the rest 11 (73%) patients had recurrent ALK-positive ALCL. Six patients developed early relapse ( 12 months after remission was achieved); 5 patients had late relapse (after 12 months of remission); local (1 site) and systemic relapses were diagnosed in 7 and 4 patients, respectively. Our patients received from 2 to 7 lines of treatment (the median is 4). In the first line of therapy, the patients were treated according to NHL-BFM based regimens (n = 9; 60%), the CHOP (n = 5; 33%), and the HyperCVAD (n = 1; 7%) protocols. In the second line of therapy, 8 (53%) patients were treated according to NHL-BFM based regimens; 2 (13%) patients were treated with GDP; 1 (7%) patient received DHAP chemotherapy; 1 (7%) patient received a combination of methotrexate and vinblastine (MTX + V); 1 (7%) patient received bendamustine as a single agent. Two (13%) patients were treated with chemotherapy in combination with targeted drugs (GDP + BV, n = 1; NHL-BFM + crizotinib, n = 1). As a third or subsequent line of treatment, the patients received a variety of chemotherapy regimens (n = 5; 33%) and chemotherapy in combination with targeted drugs (n = 10; 67%). Five (33%) patients underwent ALK-inhibitor therapy (crizotinib (n = 4) and ceritinib (n = 1)). Seven (46%) patients were treated with BV (BV as a single agent (n = 4) and BV + chemotherapy (n = 3)). The median number of treatment lines before autologous HSCT (auto-HSCT) and allogeneic HSCT (allo-HSCT) was 2 (2–3) and 3 (3–4), respectively. Auto-HSCT was carried out in 11 (73%) cases. Nine (60%) patients underwent allo-HSCT (from a matched unrelated donor (n = 6), from a matched related donor (n = 2), and from a haploidentical donor (n = 1)). One patient received NK cells from a haploidentical donor as maintenance. In 5 (33%) cases, alloHSCT was carried out following auto-HSCT. The conditioning regimens (CR) used for auto-HSCT included BEAM (carmustine – 300 mg/m2, etoposide – 800 mg/m2, Cytosar – 1600 mg/m2, melphalan – 140 mg/m2) – in 5 (45%) patients; BeEAM (bendamustine – 320 mg/m2, etoposide – 800 mg/m2, Cytosar – 1600 mg/m2, melphalan – 140 mg/m2) – in 5 (45%) patients; and BuCy (Cyclophosphan – 100 mg/kg, busulfan – 14 mg/kg) – in 1 (10%) case. Seven (78%) patients undergoing allo-HSCT received the FluBenda conditioning regimen (fludarabine – 90–150 mg/m2, bendamustine – 390 mg/m2) and post-transplant Cyclophosphan and calcineurin inhibitors for the prevention of graft-versus-host disease (GVHD) (n = 7; 78%); one (11%) patient received the FluMel regimen (fludarabine – 150 mg/m2, melphalan – 140 mg/m2) and CsA/MTX (Cyclosporin А, methotrexate) for GVHD prevention; and in 1 case (11%) data on the RC and GVHD prophylaxis were missing. Overall response to the second line of treatment was achieved in 10 (67%) patients, with complete response observed in 7 (47%) cases, and partial response –in 3 (20%) cases. Five out of the 7 patients treated with BV during different lines of therapy managed to achieve complete response. Four out of the 5 patients who had undergone treatment with ALK inhibitors, demonstrated complete response. The 10-year overall survival (OS) rate of the study patients reached 90% (95% confidence interval (CI) 47–99). The 10-year progression-free survival (PFS) rate after the second line of treatment was 39% (95% CI 13–64). The 10-year OS and PFS rates after auto-HSCT were 100% and 35% (95% CI 8–64) respectively....
- 14 February 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (1) , 22-31
Open AccessThe treatment of relapsed/refractory anaplastic large cell lymphoma expressing the anaplastic lymphoma kinase: a single-center experience
Anaplastic large cell lymphoma (ALCL) expressing the anaplastic lymphoma kinase (ALK) (ALK+ ALCL) is a rare type of lymphoma which comprises 10-15% of all non-Hodgkin lymphomas in children and 2–3% in young adults. Relapsed/refractory disease occurs even more rarely (25–40% of all cases). There is as yet no standard treatment for relapsed/refractory ALK+ ALCL. Patients with ALK+ ALCL usually present at advanced stages of the disease with extranodal involvement (skin, soft tissues, bones, lungs, liver, spleen and bone marrow) and B symptoms. ALK-positive ALCL affects males more often than females. There are two morphological variants: the common type (65% of cases) and the non-common type which is associated with a poorer prognosis. ALK+ ALCLs are often associated with t(2;5) and t(1;2), resulting in the formation of the NPM-ALK and the TPM3-ALK fusion proteins, respectively. Data about the treatment of relapsed/refractory ALK+ ALCL are limited. Earlier, targeted therapies (brentuximab vedotin (BV), ALK inhibitors) and risk-adapted chemotherapy followed by hematopoietic stem cell transplantation (HSCT) for remission consolidation were shown to be highly effective. A total of 15 patients with relapsed/refractory ALK+ ALCL were treated at the R.M. Gorbacheva Research Institute starting from 2002. Fourteen (93%) patients had ALK-positive ALCL of common morphology and one (7%) patient had the non-common variant (histiocytic). The study was approved by the Independent Ethics Committee and the Scientific Council of the Pavlov University. The expression of CD3 on tumor cells was assessed (CD3 positive: n = 4 (27%), CD3 negative: n = 8 (53%), no data: n = 3 (20%). The median age at the diagnosis was 26 years (11 months– 37 years). The median follow-up from the diagnosis was 9 years (1–19 years). Nine (60%) patients were aged 18 years and six (40%) patients were aged 18 years. There were 10 (67%) males and 5 (33%) females. At onset, 2 (13%) patients were diagnosed with early-stage disease (stage II), while the others were diagnosed with advanced-stage disease: 2 (13%) patients had stage III disease and 11 (74%) had stage IV disease. Staging was performed according to the St. Jude staging system (in children) and the Ann Arbour staging classification (in adults). Thirteen (86%) patients had extranodal involvement. Four (27%) patients had refractory disease (progression within the first three months or the absence of complete remission after the first-line treatment) and the rest 11 (73%) patients had recurrent ALK-positive ALCL. Six patients developed early relapse ( 12 months after remission was achieved); 5 patients had late relapse (after 12 months of remission); local (1 site) and systemic relapses were diagnosed in 7 and 4 patients, respectively. Our patients received from 2 to 7 lines of treatment (the median is 4). In the first line of therapy, the patients were treated according to NHL-BFM based regimens (n = 9; 60%), the CHOP (n = 5; 33%), and the HyperCVAD (n = 1; 7%) protocols. In the second line of therapy, 8 (53%) patients were treated according to NHL-BFM based regimens; 2 (13%) patients were treated with GDP; 1 (7%) patient received DHAP chemotherapy; 1 (7%) patient received a combination of methotrexate and vinblastine (MTX + V); 1 (7%) patient received bendamustine as a single agent. Two (13%) patients were treated with chemotherapy in combination with targeted drugs (GDP + BV, n = 1; NHL-BFM + crizotinib, n = 1). As a third or subsequent line of treatment, the patients received a variety of chemotherapy regimens (n = 5; 33%) and chemotherapy in combination with targeted drugs (n = 10; 67%). Five (33%) patients underwent ALK-inhibitor therapy (crizotinib (n = 4) and ceritinib (n = 1)). Seven (46%) patients were treated with BV (BV as a single agent (n = 4) and BV + chemotherapy (n = 3)). The median number of treatment lines before autologous HSCT (auto-HSCT) and allogeneic HSCT (allo-HSCT) was 2 (2–3) and 3 (3–4), respectively. Auto-HSCT was carried out in 11 (73%) cases. Nine (60%) patients underwent allo-HSCT (from a matched unrelated donor (n = 6), from a matched related donor (n = 2), and from a haploidentical donor (n = 1)). One patient received NK cells from a haploidentical donor as maintenance. In 5 (33%) cases, alloHSCT was carried out following auto-HSCT. The conditioning regimens (CR) used for auto-HSCT included BEAM (carmustine – 300 mg/m2, etoposide – 800 mg/m2, Cytosar – 1600 mg/m2, melphalan – 140 mg/m2) – in 5 (45%) patients; BeEAM (bendamustine – 320 mg/m2, etoposide – 800 mg/m2, Cytosar – 1600 mg/m2, melphalan – 140 mg/m2) – in 5 (45%) patients; and BuCy (Cyclophosphan – 100 mg/kg, busulfan – 14 mg/kg) – in 1 (10%) case. Seven (78%) patients undergoing allo-HSCT received the FluBenda conditioning regimen (fludarabine – 90–150 mg/m2, bendamustine – 390 mg/m2) and post-transplant Cyclophosphan and calcineurin inhibitors for the prevention of graft-versus-host disease (GVHD) (n = 7; 78%); one (11%) patient received the FluMel regimen (fludarabine – 150 mg/m2, melphalan – 140 mg/m2) and CsA/MTX (Cyclosporin А, methotrexate) for GVHD prevention; and in 1 case (11%) data on the RC and GVHD prophylaxis were missing. Overall response to the second line of treatment was achieved in 10 (67%) patients, with complete response observed in 7 (47%) cases, and partial response –in 3 (20%) cases. Five out of the 7 patients treated with BV during different lines of therapy managed to achieve complete response. Four out of the 5 patients who had undergone treatment with ALK inhibitors, demonstrated complete response. The 10-year overall survival (OS) rate of the study patients reached 90% (95% confidence interval (CI) 47–99). The 10-year progression-free survival (PFS) rate after the second line of treatment was 39% (95% CI 13–64). The 10-year OS and PFS rates after auto-HSCT were 100% and 35% (95% CI 8–64) respectively....